Etoposide

Generic Name
Etoposide
Brand Names
Etopophos, Toposar, Vepesid
Drug Type
Small Molecule
Chemical Formula
C29H32O13
CAS Number
33419-42-0
Unique Ingredient Identifier
6PLQ3CP4P3
Background

A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to ce...

Indication

For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.

Associated Conditions
Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer
Associated Therapies
-
Clinical Trials
Related News

Combination Chemotherapy and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer

First Posted Date
2003-01-27
Last Posted Date
2016-07-19
Lead Sponsor
Alliance for Clinical Trials in Oncology
Target Recruit Count
65
Registration Number
NCT00033696
Locations
🇺🇸

Cedars-Sinai Medical Center, Los Angeles, California, United States

🇺🇸

CCOP - Northern Indiana CR Consortium, South Bend, Indiana, United States

🇺🇸

University of Massachusetts Memorial Medical Center - University Campus, Worcester, Massachusetts, United States

and more 48 locations

Combination Chemotherapy in Treating Children With Neuroblastoma

First Posted Date
2003-01-27
Last Posted Date
2014-08-01
Lead Sponsor
Children's Oncology Group
Target Recruit Count
573
Registration Number
NCT00003093
Locations
🇺🇸

Columbus Children's Hospital, Columbus, Ohio, United States

🇺🇸

Cancer Research Center of Hawaii, Honolulu, Hawaii, United States

🇺🇸

MBCCOP - Hawaii, Honolulu, Hawaii, United States

and more 231 locations

TITLE:Less Intensive Therapy for Children With Non-Hodgkin's Lymphoma

First Posted Date
2003-01-27
Last Posted Date
2014-07-24
Lead Sponsor
Children's Oncology Group
Target Recruit Count
1148
Registration Number
NCT00002757
Locations
🇫🇷

Institut Gustave Roussy, Villejuif, France

🇬🇧

Children's Hospital - Sheffield, Sheffield, England, United Kingdom

Filgrastim Compared With Sargramostim Plus Chemotherapy, Peripheral Stem Cell Transplantation, and Interferon Alfa in Treating Patients With Multiple Myeloma

First Posted Date
2003-01-27
Last Posted Date
2017-11-29
Lead Sponsor
Masonic Cancer Center, University of Minnesota
Target Recruit Count
87
Registration Number
NCT00005987
Locations
🇺🇸

University of Minnesota Cancer Center, Minneapolis, Minnesota, United States

Comparison of Two Combination Chemotherapy Regimens in Treating Adults With Previously Untreated Leukemia or Lymphoma

First Posted Date
2003-01-27
Last Posted Date
2016-02-22
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
170
Registration Number
NCT00002766
Locations
🇺🇸

Stanford Cancer Center at Stanford University Medical Center, Stanford, California, United States

🇺🇸

Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States

🇺🇸

Winship Cancer Institute of Emory University, Atlanta, Georgia, United States

and more 4 locations

Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Stage III or Stage IV Hodgkin's Lymphoma

First Posted Date
2003-01-27
Last Posted Date
2023-11-09
Lead Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Target Recruit Count
552
Registration Number
NCT00049595
Locations
🇳🇱

Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands

🇧🇪

Clinique Universitaire De Mont-Godinne, Yvoir, Belgium

🇦🇺

Canberra Hospital, Garran, Australian Capital Territory, Australia

and more 137 locations

Combination Chemotherapy in Treating Patients With Advanced Hodgkin's Lymphoma

First Posted Date
2003-01-27
Last Posted Date
2020-08-12
Lead Sponsor
Stanford University
Target Recruit Count
50
Registration Number
NCT00002715
Locations
🇺🇸

Stanford Cancer Center at Stanford University Medical Center, Stanford, California, United States

Cisplatin and Etoposide Prior to Radiation Therapy in Treating Patients With CNS Tumors

First Posted Date
2003-01-27
Last Posted Date
2011-03-15
Lead Sponsor
Mayo Clinic
Registration Number
NCT00002472
Locations
🇺🇸

Mayo Clinic Cancer Center, Rochester, Minnesota, United States

🇺🇸

Mayo Clinic Scottsdale, Scottsdale, Arizona, United States

🇺🇸

Mayo Clinic - Jacksonville, Jacksonville, Florida, United States

Combination Chemotherapy in Treating Children With Non-Hodgkin's Lymphoma

Phase 3
Completed
Conditions
Lymphoma
First Posted Date
2003-01-27
Last Posted Date
2021-02-21
Lead Sponsor
UNICANCER
Target Recruit Count
179
Registration Number
NCT00003650
Locations
🇫🇷

Centre Leon Berard, Lyon, France

Combination Chemotherapy Plus Steroid Therapy in Treating Children With Acute Lymphoblastic Leukemia or Lymphoblastic Non-Hodgkin's Lymphoma

Phase 3
Conditions
Leukemia
Lymphoma
First Posted Date
2003-01-27
Last Posted Date
2011-01-21
Lead Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Target Recruit Count
1500
Registration Number
NCT00003728
Locations
🇵🇹

Hospital Escolar San Joao, Porto, Portugal

🇵🇹

Instituto Portugues de Oncologia Centro do Porto, SA, Porto, Portugal

🇫🇷

CHR de Besancon - Hopital Saint-Jacques, Besancon, France

and more 20 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy